Distinguished in Small Cell Lung Cancer (SCLC)

Lionel Falchero

L'Hôpital Nord Ouest
Villefranche-sur-saone, FR 
Distinguished in Small Cell Lung Cancer (SCLC)
L'Hôpital Nord Ouest
Villefranche-sur-saone, FR 
OverviewLocationsClinical Research

Overview

Lionel Falchero practices in Villefranche-sur-saone, France. Mr. Falchero is rated as a Distinguished expert by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.

His clinical research consists of co-authoring 56 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles and participated in 1 clinical trial in the study of Small Cell Lung Cancer (SCLC).

Gender
Male

Locations

L'Hôpital Nord Ouest
Villefranche-sur-saone, France
Other Locations
HIA Saint Anne
Toulon, France
Gleize, France
Creteil, France
CHU Pontchaillou
Rennes, France
CHU Morvan
Brest, France
chu de Limoges
Limoges, France
Dieppe, 76200, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Evaluation of Non-Invasive Ventilation Preoperative Lung Resection Surgery
Evaluation of Non-Invasive Ventilation Preoperative Lung Resection Surgery
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Device
Study Phase: Not Applicable
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2025
Intervention Type: Other
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy
Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Drug
Study Drugs: Vargatef®, Docetaxel
Study Phase: Phase 2
Multicenter Prospective Study of the Efficacy of Stereotactic Lung Radiation Therapy After Concomitant Radio-chemotherapy for Unresectable Stage III Non-small Cell Lung Carcinoma (NSCLC) With Peripheral Primary Tumor.
Multicenter Prospective Study of the Efficacy of Stereotactic Lung Radiation Therapy After Concomitant Radio-chemotherapy for Unresectable Stage III Non-small Cell Lung Carcinoma (NSCLC) With Peripheral Primary Tumor.
Enrollment Status: Terminated
Publish Date: February 09, 2021
Intervention Type: Radiation
Study Phase: Not Applicable
Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases
Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases
Enrollment Status: Terminated
Publish Date: February 01, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 3
View 5 Less Clinical Trials

56 Total Publications

Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.
Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.
Journal: NEJM evidence
Published: June 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Falchero's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile